Literature DB >> 25104528

Switching patients from blinded study drug to warfarin at the end of the ENGAGE AF-TIMI 48 trial: setting a new standard.

John W Eikelboom1, Thomas Vanassche2, Stuart J Connolly3.   

Abstract

Entities:  

Keywords:  apixaban; atrial fibrillation; edoxaban; rivaroxaban; warfarin

Mesh：

Substances：

Year:  2014        PMID： 25104528     DOI： 10.1016/j.jacc.2014.06.008

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  2 in total

1.  Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.

Authors:  Gilles R Dagenais; Leanne Dyal; Jacqueline J Bosch; Darryl P Leong; Victor Aboyans; Scott D Berkowitz; Deepak L Bhatt; Stuart J Connolly; Keith A A Fox; Eva Muehlhofer; Jeffrey L Probstfield; Petr Widimsky; Bernhard R Winkelmann; Salim Yusuf; John W Eikelboom
Journal:  Heart       Date:  2021-05-21       Impact factor: 5.994

2.  2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.

Authors:  Chern-En Chiang; Ken Okumura; Shu Zhang; Tze-Fan Chao; Chung-Wah Siu; Toon Wei Lim; Anil Saxena; Yoshihide Takahashi; Wee Siong Teo
Journal:  J Arrhythm       Date:  2017-06-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.